Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, Scott BB, Panebianco D, Ding Y, Gottesdiener K, Wagner JA. Stoch SA, et al. Among authors: van bortel l. Br J Clin Pharmacol. 2013 May;75(5):1240-54. doi: 10.1111/j.1365-2125.2012.04471.x. Br J Clin Pharmacol. 2013. PMID: 23013236 Free PMC article. Clinical Trial.
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN 3rd, Van Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, Van Bortel LM, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM, Wagner JA. Krishna R, et al. Among authors: van hoydonck p, van dyck k, van bortel lm. Clin Pharmacol Ther. 2008 Dec;84(6):679-83. doi: 10.1038/clpt.2008.109. Epub 2008 Jun 25. Clin Pharmacol Ther. 2008. PMID: 18580870 Clinical Trial. No abstract available.
Propionyl-L-carnitine for intermittent claudication.
Kamoen V, Vander Stichele R, Campens L, De Bacquer D, Van Bortel L, de Backer TL. Kamoen V, et al. Among authors: van bortel l. Cochrane Database Syst Rev. 2021 Dec 26;12(12):CD010117. doi: 10.1002/14651858.CD010117.pub2. Cochrane Database Syst Rev. 2021. PMID: 34954832 Free PMC article. Review.
Indirect implications of COVID-19 prevention strategies on non-communicable diseases : An Opinion Paper of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk Assessment in Subjects Living in or Emigrating from Low Resource Settings.
Modesti PA, Wang J, Damasceno A, Agyemang C, Van Bortel L, Persu A, Zhao D, Jarraya F, Marzotti I, Bamoshmoosh M, Parati G, Schutte AE. Modesti PA, et al. Among authors: van bortel l. BMC Med. 2020 Aug 14;18(1):256. doi: 10.1186/s12916-020-01723-6. BMC Med. 2020. PMID: 32795303 Free PMC article.
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, Laethem T, Rasmussen S, van Bortel L, van Lancker G, Iwamoto M. Khalilieh SG, et al. Among authors: van bortel l. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02016-18. doi: 10.1128/AAC.02016-18. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30783000 Free PMC article.
241 results